




Searching News Database: Cancer Immunotherapy
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
HSMN NewsFeed - 17 Nov 2023
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
HSMN NewsFeed - 9 Jan 2023
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 23 Jul 2021
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 10 Aug 2020
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
HSMN NewsFeed - 19 May 2020
BioEclipse Therapeutics(TM) Announces Move to New Corporate Headquarters in Mountain View, CA
BioEclipse Therapeutics(TM) Announces Move to New Corporate Headquarters in Mountain View, CA
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 12 Mar 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 16 Dec 2019
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
HSMN NewsFeed - 22 Nov 2019
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
HSMN NewsFeed - 12 Sep 2019
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
HSMN NewsFeed - 3 Dec 2018
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
HSMN NewsFeed - 30 Aug 2018
RootPath Raises $7 Million Seed Round led by Sequoia China to Accelerate Its Cancer Immunotherapy Programs
RootPath Raises $7 Million Seed Round led by Sequoia China to Accelerate Its Cancer Immunotherapy Programs
HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
HSMN NewsFeed - 28 Jun 2018
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
HSMN NewsFeed - 3 Jan 2018
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 28 Aug 2017
MedGenome Secures $30 Million Series C Funding Led by Sequoia India and Sofina
MedGenome Secures $30 Million Series C Funding Led by Sequoia India and Sofina
HSMN NewsFeed - 12 Jul 2017
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
HSMN NewsFeed - 7 Dec 2016
CytoSorb(R) Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
CytoSorb(R) Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
HSMN NewsFeed - 22 Nov 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
HSMN NewsFeed - 11 Nov 2016
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
HSMN NewsFeed - 10 Jun 2016
AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development
AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 6 Jan 2016
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
HSMN NewsFeed - 19 Oct 2015
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
HSMN NewsFeed - 1 Oct 2015
Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies
Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
HSMN NewsFeed - 23 Apr 2015
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
HSMN NewsFeed - 10 Jul 2014
Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer
Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer
HSMN NewsFeed - 9 Jun 2014
Batu Biologics Announces FDA Development Plans for ValloVax(TM) Angiogenesis-Targeting Cancer Vaccine
Batu Biologics Announces FDA Development Plans for ValloVax(TM) Angiogenesis-Targeting Cancer Vaccine
HSMN NewsFeed - 14 Apr 2014
Kite Pharma Expands Leadership Team and Announces Senior Management Promotions
Kite Pharma Expands Leadership Team and Announces Senior Management Promotions
HSMN NewsFeed - 11 Apr 2014
Kite Pharma Expands Company's Board of Directors with the Appointment of Jonathan M. Peacock
Kite Pharma Expands Company's Board of Directors with the Appointment of Jonathan M. Peacock
HSMN NewsFeed - 13 Jan 2014
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
HSMN NewsFeed - 3 Dec 2012
ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
HSMN NewsFeed - 29 Oct 2012
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
HSMN NewsFeed - 14 Jul 2009
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
HSMN NewsFeed - 4 Jun 2009
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 22 Oct 2007
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
HSMN NewsFeed - 11 Jul 2007
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
HSMN NewsFeed - 12 Jun 2007
CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
HSMN NewsFeed - 31 Oct 2006
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
Additional items found! 99

Members Archive contains
99 additional stories matching:
Cancer Immunotherapy
(Password required)
Cancer Immunotherapy
(Password required)